@article{CJCR4358,
author = {Bo Jia and Yuankai Shi and Mei Dong and Fengyi Feng and Sheng Yang and Hua Lin and Liqiang Zhou and Shengyu Zhou and Shanshan Chen and Jianliang Yang and Peng Liu and Yan Qin and Changgong Zhang and Lin Gui and Lin Wang and Xue Wang and Xiaohui He},
title = {Clinical features, survival and prognostic factors of primary testicular diffuse large B-cell lymphoma},
journal = {Chinese Journal of Cancer Research},
volume = {26},
number = {4},
year = {2014},
keywords = {},
abstract = {Objective: To assess the clinical features, survival and prognostic factors of primary testicular diffuse large B-cell lymphoma (DLBCL).
Methods: A retrospective study of 37 patients with primary testicular DLBCL was carried out from November 2003 to May 2012. Their clinical features, survival and prognostic factors were analyzed.
Results: During a median follow-up period of 39.8 months (5.4-93.0 months), the median progression-free survival (PFS) was 26.2 months (95% CI: 0-65 months) and the 3-year overall survival (OS) rate was 78.4%. Within the whole cohort, the factors significantly associated with a superior PFS were limited stage (stage I/II), lactate dehydrogenase (LDH) ≤245 U/L, international prognostic index (IPI) ≤1, primary tumor diameter <7.5 cm, and patients who had complete response (CR) and received doxorubicin-contained chemotherapy (P<0.05). There was a trend toward superior outcome for patients who received combined therapy (surgery/chemotherapy/radiotherapy) (P=0.055). Patients who had CR, primary tumor diameter <7.5 cm and IPI score ≤1 were significantly associated with longer PFS at multivariate analysis.
Conclusions: Primary testicular DLBCL had poorer survival. CR, primary tumor diameter and IPI were independent prognostic factors. The combined therapy of orchectomy, doxorubicin-contained chemotherapy and contralateral testicular radiotherapy (RT) seemed to improve survival.},
issn = {1993-0631}, url = {https://cjcr.amegroups.org/article/view/4358}
}